|Company name||Y-mAbs Therapeutics, Inc.|
NEW YORK, October 9, 2020 – Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) on behalf of Y-mAbs stockholders. Our investigation concerns whether Y-mAbs has violated the federal securities laws and/or engaged in other unlawful business practices.
On October 5, 2020, Y-mAbs issued a press release disclosing receipt of “a Refusal to File letter from the U.S. Food and Drug Administration (‘FDA’) regarding the Biologics License Application (‘BLA’) for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma, which was submitted in August 2020.”
Y-mAbs advised investors that “[u]pon preliminary review, the FDA determined that certain parts of the Chemistry, Manufacturing and Control (‘CMC’) module and the Clinical module of the BLA require further detail.”
On this news, y-mAbs’s stock price fell $3.57 per share, or 8.56%, to close at $38.13 per share on October 6, 2020.
If you purchased or otherwise acquired Y-mAbs shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.